Cinda Biorecoa Biorecized Whole Human Source Anti-CD47 Monoclonal Antibody Injection (IBI188) Phase I Clinical Study Completes First Patient Administration
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Cinda Bio announced that its self-developed recombinant whole human source anti-CD47 monoclonal antibody injection (research code: IBI188) Phase I clinical study completed the first patient administrationthis study is a Phase I clinical study conducted in China to assess the safety, tolerability and initial effectiveness of IBI188 subjects for the treatment of advanced malignanciesthe main purpose of thestudy was to assess the safety, tolerance and phase II recommended dose of IBI188 monodothesandand and different combination synopsis in subjects with advanced malignanciesIBI188 is an important product in Cinda Bio-Oncologyproduct(http://pipelineCD47 is one of the key members of the body's immunosuppressive signaling pathway, unlike PD-1, PD-L1 and CTLA-4, which act on T-cell immunedetectingsignals at the(http:// point, CD47 inhibits the phagocytophic effect by acting mainly with the inhibitory receptor SIRP alphathere is evidence that anti-CD47 mono-anti-monodrugand or combination of otherdrugs(http://have better efficacy in recurrent/incurable non-Hodgkin's lymphoma and multiple solid tumorssinta bio
Cinda Bio
Pharmaceutical (http:// (Hong Kong Stock Exchange Code: 01801), is a biopharmaceutical company (http:// ) dedicated to the development, production and sale of new new drugs (http:// for the treatment of major diseases such as cancer, autoimmune diseases
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
